BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1684188)

  • 1. Overview of the role of mupirocin.
    Lamb YJ
    J Hosp Infect; 1991 Sep; 19 Suppl B():27-30. PubMed ID: 1684188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents.
    Watanakunakorn C; Axelson C; Bota B; Stahl C
    Am J Infect Control; 1995 Oct; 23(5):306-9. PubMed ID: 8585642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience.
    Hudson IR
    J Hosp Infect; 1994 Jun; 27(2):81-98. PubMed ID: 7930545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hospital personnel who are nasal carriers of methicillin-resistant Staphylococcus aureus. Usefulness of treatment with mupirocin].
    Gaspar MC; Uribe P; Sánchez P; Coello R; Cruzet F
    Enferm Infecc Microbiol Clin; 1992 Feb; 10(2):107-10. PubMed ID: 1643130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Ward A; Campoli-Richards DM
    Drugs; 1986 Nov; 32(5):425-44. PubMed ID: 3098541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus.
    Bertino JS
    Am J Health Syst Pharm; 1997 Oct; 54(19):2185-91. PubMed ID: 9331438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal dose requirements for nasal mupirocin and its role in the control of epidemic MRSA.
    Casewell MW; Hill RL
    J Hosp Infect; 1991 Sep; 19 Suppl B():35-40. PubMed ID: 1684191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal carriage of meticillin resistant Staphylococcus aureus: the prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients.
    Lederer SR; Riedelsdorf G; Schiffl H
    Eur J Med Res; 2007 Jul; 12(7):284-8. PubMed ID: 17933699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus.
    Parras F; Guerrero MC; Bouza E; Blázquez MJ; Moreno S; Menarguez MC; Cercenado E
    Antimicrob Agents Chemother; 1995 Jan; 39(1):175-9. PubMed ID: 7695302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-ranging study to assess the application of intranasal 2% mupirocin calcium ointment to eradicate Staphylococcus aureus nasal colonization.
    Mehta MS; Hacek DM; Kufner BA; Price C; Peterson LR
    Surg Infect (Larchmt); 2013 Feb; 14(1):69-72. PubMed ID: 23448592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective?
    Walker ES; Vasquez JE; Dula R; Bullock H; Sarubbi FA
    Infect Control Hosp Epidemiol; 2003 May; 24(5):342-6. PubMed ID: 12785407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis.
    Bloom BS; Fendrick AM; Chernew ME; Patel P
    Am J Kidney Dis; 1996 May; 27(5):687-94. PubMed ID: 8629629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agents for the decolonization of methicillin-resistant Staphylococcus aureus.
    McConeghy KW; Mikolich DJ; LaPlante KL
    Pharmacotherapy; 2009 Mar; 29(3):263-80. PubMed ID: 19249946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak.
    Hill RL; Duckworth GJ; Casewell MW
    J Antimicrob Chemother; 1988 Sep; 22(3):377-84. PubMed ID: 3141347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of mupirocin in the prevention of infections with meticillin-resistant Staphylococcus aureus in a gastroenterology unit.
    Dupeyron C; Campillo B; Richardet JP; Soussy CJ
    J Hosp Infect; 2006 Aug; 63(4):385-92. PubMed ID: 16772100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin.
    Pérez-Fontán M; Rosales M; Rodríguez-Carmona A; Moncalián J; Fernández-Rivera C; Cao M; Valdés F
    Adv Perit Dial; 1992; 8():242-5. PubMed ID: 1361797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of methicillin-resistant Staphylococcus aureus (MRSA) throat carriage: a randomised trial comparing topical treatment with rifampicin-based systemic therapy.
    Lindgren AK; Nilsson AC; Åkesson P; Gustafsson E; Melander E
    Int J Antimicrob Agents; 2018 Apr; 51(4):642-645. PubMed ID: 28843819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of calcium mupirocin in the eradication of nasal Staphylococcus aureus carriage.
    Redhead RJ; Lamb YJ; Rowsell RB
    Br J Clin Pract; 1991; 45(4):252-4. PubMed ID: 1810357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review.
    Laupland KB; Conly JM
    Clin Infect Dis; 2003 Oct; 37(7):933-8. PubMed ID: 13130405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study.
    Wertheim HF; Vos MC; Ott A; Voss A; Kluytmans JA; Vandenbroucke-Grauls CM; Meester MH; van Keulen PH; Verbrugh HA
    Ann Intern Med; 2004 Mar; 140(6):419-25. PubMed ID: 15023707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.